RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
Joinn Labs undermined by AI as FDA phases out animal drug testing
The outsourced clinical research services provider’s shares tumbled after the U.S. drug regulator announced a new approach to drug testing Key Takeaways: Joinn Labs’ shares fell on heavy trading as…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
Recent Articles
BRIEF: Autohome slashes headcount as revenue sags
2518.HK
ATHM.US
BRIEF: Drinda New Energy rises in Hong Kong trading debut
2865.HK
002865.SHE
RELATED ARTICLES
-
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK -
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Property crisis deepens with debt action against Sunac
1918.HK
-
Country Garden’s debt restructure hinges on stabilizing property market
2007.HK
-
BRIEF: Fosun Tourism may have dropped into the red last year
1992.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
Battered Lanvin hopes for better 2025 as executive revolving door keeps turning
LANV.US
